Show simple item record

dc.contributor.authorKean, JD
dc.contributor.authorSarris, J
dc.contributor.authorScholey, A
dc.contributor.authorSilberstein, R
dc.contributor.authorDowney, LA
dc.contributor.authorStough, C
dc.date.accessioned2020-12-22T02:34:57Z
dc.date.available2020-12-22T02:34:57Z
dc.date.issued2017-02-01
dc.identifierpii: 10.1007/s00213-016-4471-y
dc.identifier.citationKean, J. D., Sarris, J., Scholey, A., Silberstein, R., Downey, L. A. & Stough, C. (2017). Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524A (R)) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. PSYCHOPHARMACOLOGY, 234 (3), pp.403-420. https://doi.org/10.1007/s00213-016-4471-y.
dc.identifier.issn0033-3158
dc.identifier.urihttp://hdl.handle.net/11343/257666
dc.description.abstractINTRODUCTION: This study investigated the effects of a marine oil extract (PCSO-524®) on inattention, hyperactivity, mood and cognition in children and adolescents. PCSO-524® is a standardised lipid extract of the New Zealand green-lipped mussel and is an inflammatory modulator that inhibits the 5'-lipoxygenase and cyclooxygenase pathways and decreases concentrations of the pro-inflammatory arachidonic acid (AA). METHODS: PCSO-524® or a matched placebo was administered for 14 weeks to 144 participants (123 males/21 females; mean age 8.7 years) with high hyperactivity and inattention in a randomised, double-blind, placebo-controlled study. The primary outcome was the Conners Parent Rating Scale assessing parental reports of behavioural problems. Secondary outcomes assessed changes in cognition and mood. RESULTS: The results of the present study did not support the hypothesis that PCSO-524® improves parental reports of hyperactivity, inattention and impulsivity in children ages 6 to 14 years over placebo. Repeated measures ANOVA on post hoc subsample analysis indicated significant improvements in hyperactivity (p = 0.04), attention (p = 0.02), learning (p = 0.05) and probability of ADHD (p = 0.04) with a medium to large average effect size (d = 0.65) in those children who did not meet criteria for combined hyperactivity and inattention. Furthermore, significant improvements in the PCSO-524® group were indicated in a whole sample repeated measures ANCOVA on recognition memory between baseline and week 8 over placebo (p = 0.02, d = 0.56); this difference was not sustained at week 14. CONCLUSIONS: The results presented indicate that PCSO-524® may be beneficial in reducing levels of hyperactivity and inattention in a population of children with clinical and subclinical symptoms of ADHD.
dc.languageEnglish
dc.publisherSPRINGER
dc.titleReduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524A (R)) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial
dc.typeJournal Article
dc.identifier.doi10.1007/s00213-016-4471-y
melbourne.affiliation.departmentPsychiatry
melbourne.affiliation.departmentCentre for Youth Mental Health
melbourne.source.titlePsychopharmacology
melbourne.source.volume234
melbourne.source.issue3
melbourne.source.pages403-420
dc.rights.licenseCC BY
melbourne.elementsid1121574
melbourne.contributor.authorSarris, Jerome
melbourne.contributor.authorKean, James
dc.identifier.eissn1432-2072
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record